Compare Medpace Holdings Inc (MEDP) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Merck & Co., Inc. — how do they compare? Medpace Holdings Inc trades at $530.32 (market cap $15.08B), while Merck & Co., Inc. trades at $125.4 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 20.4× Medpace Holdings Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MRK | |
|---|---|---|
Market Cap | $15.08B | $307.25B |
Sector | Technology | Health |
52-Week High | $620.59 | $129.52 |
52-Week Low | $308.88 | $77.60 |
Enterprise Value | $14.55B | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MRK trades at $125.85, down 1.29% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30 suggesting 9% upside. Recent earnings have consistently beaten expectations, with Q1 2026 loss narrower than forecast. The company maintains strong profitability with a 73.91% gross margin and 18.97% ROE, while actively expanding its pipeline through acquisitions like Terns Pharmaceuticals.
Outlook remains positive driven by earnings beats and strategic M&A, but risks include rising debt levels and patent expirations. The stock offers a dividend yield with upcoming payment, supported by institutional accumulation. Valuation multiples are elevated, requiring sustained growth to justify current levels amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
